Insights: Events Written Description Across Technologies

KTIPS (Kilpatrick Townsend Intellectual Property Seminars)

Written description jurisprudence in the life sciences has been mainly focused on antibody technology whether functional language is sufficient to claim a genus (AbbVie Deutschland v. Janssen Biotech (Fed. Cir. 2014)) or whether a novel antigen is sufficient to claim an antibody which binds to the antigen (Amgen Inc. v. Sanofi (Fed. Cir. 2017)). More recently, the Federal Circuit has issued guidance with respect to written description sufficiency for small molecules (Idenix v. Gilead (Fed. Cir. 2019)) and therapeutic compositions (Nuvo Pharmaceuticals v. Dr. Reddy’s Lab (Fed. Cir. 2019)). This session will explore these cases and provide strategies around life science portfolio building by ensuring that applications have sufficient written description support. Our discussion will further explore whether life science innovations seem to face more frequent and/or stricter written-description requirements at the USPTO or in court cases relative to software innovations.

Event Details

Monday, August 3, 2020


Virtual

9:00 a.m. - 10:00 a.m. PST

Upcoming Events

Latest Thinking

View more Insights
Insights Center
close
Loading...
If you would like to receive related insights and information from Kilpatrick Townsend, please provide your contact details by filling out the form and clicking “Agree.” If you would like to access the PDF only, please click “Download Only.”